Olink

Olink®
Part of Thermo Fisher Scientific

Filters

PublicationDisease areaApplication areaSample typeProducts

Scientific Reports, 2025
Untargeted metabolomic and proteomic analysis implicates SIRT2 as a novel therapeutic target for diabetic nephropathy

Zhang R., Chang R., Wang H. et al.

Olink Target 96Metabolic DiseasesNephrologyPathophysiologySerum

Cell Death Discovery, 2025
Pan-caspase inhibitors induce secretion of HIV-1 latency reversal agent lymphotoxin-alpha from cytokine-primed NK cells

Hajikhezri Z., Zygouras I., Sönnerborg A. et al.

Olink Explore 3072/384Infectious DiseasesPathophysiologyCell Culture Supernatant

Translational Vision Science & Technology, 2025
Genetics of Circulating Inflammatory Proteins and Iridocyclitis: An Exploratory Mendelian Randomization Study

Liu H., Li F., Wang F. et al.

Olink Target 96Immunological & Inflammatory DiseasesOphthalmologyPathophysiologyPlasma

Nature Cardiovascular Research, 2025
Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction

Rasooly D., Giambartolomei C., Peloso G. et al.

Olink Explore 3072/384CVDPathophysiologyPlasma

eBioMedicine, 2025
Cardio-metabolic-related plasma proteins reveal biological links between cardiovascular diseases and fragility fractures: a cohort and Mendelian randomisation investigation

Michaëlsson K., Zheng R., Baron J. et al.

Olink Target 96Olink Explore 3072/384CVDAgingPathophysiologyPatient StratificationPlasma

Journal for ImmunoTherapy of Cancer, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

Wang X., Tian H., Chi Z. et al.

Olink Target 96OncologyImmunotherapyPathophysiologySerum

ImmunoTargets and Therapy, 2025
Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves’ Disease and Graves’ Ophthalmopathy

Ke C., Yu Y., Li J. et al.

Olink Explore 3072/384Immunological & Inflammatory DiseasesOphthalmologyPathophysiologyPlasma

Movement Disorders, 2025
Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [11C]PBR28 PET

Wallin J., Forsberg A., Svenningsson P.

Olink Target 96NeurologyPathophysiologyPlasmaCSF

International Journal of Chronic Obstructive Pulmonary Disease, 2025
The Mediation of Circulating Inflammatory Proteins in the Causal Pathway from Immune Cells to COPD

Yan K., Wang Y., Xin P.

Olink Target 96Respiratory DiseasesPathophysiologyPlasma

Brain Communications, 2025
An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis

van Eijk R., Steyn F., Janse van Mantgem M. et al.

Olink Target 96NeurologyPathophysiologyPlasma

Journal of Stroke and Cerebrovascular Diseases, 2025
Exploring the bidirectional relationships between alzheimer's disease and cerebral small vessel disease: Insights from mendelian randomization

Shang H., Liu T., Gong W. et al.

Olink Target 96CVDNeurologyPathophysiologyPlasma

Frontiers in Endocrinology, 2025
Proximity extension assay revealed novel inflammatory biomarkers for follicular development and ovarian function: a prospective controlled study combining serum and follicular fluid

Wang C., Feng Y., Chen Y. et al.

Olink Target 96ObstetricsPatient StratificationSerumFollicular Fluid

Nature Communications, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia

Sklavenitis-Pistofidis R., Konishi Y., Heilpern-Mallory D. et al.

Olink Target 48OncologyPathophysiologyPlasma

Nature Genetics, 2025
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups

Hoffmann T., Graff R., Madduri R. et al.

Olink Explore 3072/384OncologyPathophysiologyPlasma

Pediatric Research, 2025
Gut microbiota, inflammatory cytokines, and Kawasaki disease: a Mendelian randomization study and mediation analysis

Wang J., Dou H., Liang Q.

Olink Target 96Immunological & Inflammatory DiseasesPathophysiologyPlasma

PROTEOMICS, 2025
Comparative Analysis Between Olink‐PEA and Alamar‐NULISA Proteomic Technologies Applied to a Critically Ill COVID‐19 Cohort

Taleb S., Stephan N., Chennakkandathil S. et al.

Olink Target 96Wider Proteomics StudiesInfectious DiseasesTechnology EvaluationCross-platform ValidationPlasma

Children, 2025
Novel Inflammatory Biomarkers for Autism Spectrum Disorder Detected by Plasma Olink Proteomics

Lv T., Wang M., Kui L. et al.

Olink Target 96NeurologyPatient StatificationPlasma

Cytokine, 2025
A pilot investigation on inflammatory markers and theta burst stimulation protocol interaction along a three-month recovery course following an isolated upper limb fracture

Robitaille B., Herrero Babiloni A., Jodoin M. et al.

Olink Explore 3072/384Other Diseases & SyndromesPathophysiologySerum

Critical Care Medicine, 2025
Host Response Stratification in Malarial and Non-malarial Sepsis: A Prospective, Multicenter Analysis From Uganda

Cummings M., Lutwama J., Owor N. et al.

Olink Target 96Infectious DiseasesPatient StratificationSerum

Nature, 2025
Genetic architecture in Greenland is shaped by demography, structure and selection

Stæger F., Andersen M., Li Z. et al.

Olink Target 96Wider Proteomics StudiesPathophysiologyPlasma

2508 publications